Featured Announcements
1. $BYD Shares (01211.HK)$ : The upper limit of the repurchase price of A shares has been raised to no more than 400 yuan per share
BYD Co., Ltd. announced that the 25th meeting of the seventh board of directors of the company decided to consider and approve the “Proposal on Adjusting the Price Limit of the Company’s Share Repurchase”. After deliberation, the board of directors of the company decided to adjust the upper limit of the repurchase share price from no more than RMB 300 per share to no more than RMB 400 per share. The adjusted upper limit of the repurchase share price does not exceed 150% of the average trading price of the company’s shares in the 30 trading days prior to the resolution of the board of directors to adjust the repurchase share price upper limit.
2. $Great Wall Motor (02333.HK)$ : Sales in May fell by 7.94% year-on-year, and sales of ORA and Tank brands increased significantly against the trend
Great Wall Motor disclosed the production and sales report for May 2022. The sales volume for the month was 80,062 units, a year-on-year decrease of 7.94%; the production volume for the month was 84,288 units, a year-on-year increase of 4.12%. Among them, the sales volume of Haval brand was 41,748 units, a year-on-year decrease of 22.47%; the sales volume of WEY brand was 2,520 units, a year-on-year decrease of 16.31%; the sales volume of Great Wall pickups was 17,008 units, a year-on-year decrease of 16.70%; the sales volume of ORA brand was 10,768 units, a year-on-year increase of 199.36% . In addition, the monthly sales volume of the tank brand reached 8,018 units, a year-on-year increase of 31.66%. From January to May 2022, the cumulative sales volume was 417,339 units, a year-on-year decrease of 19.36%; from January to May 2022, the cumulative production volume was 425,478 units, a year-on-year decrease of 15.56%. In addition, 12,317 units were sold overseas in May, and a total of 49,372 units were sold from January to May. In May, 11,637 new energy vehicles were sold, and the cumulative sales from January to May was 50,910.
3. $ Junshi Bio (01877.HK)$ : Signed a license contract with Sun Yat-sen University Cancer Center
Junshi Bio announced that the Company and Sun Yat-Sen University Cancer Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-Sen University Cancer Institute) (the “Tumor Center”) signed the “Patent Application Technology Implementation License Contract” (the “License Contract”), the Company It will obtain three patent applications including “the application of a bacterium in the preparation of a synergist for immune checkpoint inhibitors” and its related technologies and rights under an exclusive license. , development, production, manufacturing and commercialization rights. The company will pay the cancer prevention and treatment center a milestone payment of no more than RMB 500 million in total according to the development and launch of related products.
4. $Ascletis Pharma-B(01672.HK)$ : The clinical trial application of the candidate drug was approved by the US FDA
Ascletis Pharma-B Announces a Drug-Drug Interaction (DDI) Study of the Company’s Wholly-Owned Subsidiary, Gan Lai Pharmaceutical Co., Ltd.’s FXR agonist ASC42 The clinical trial application has been approved by the U.S. Food and Drug Administration (FDA), and the study will provide additional support for subsequent Phase III clinical trials of ASC42 in China, the United States and the European Union.
PBC is a chronic progressive autoimmune cholestatic disease that often progresses to liver fibrosis and cirrhosis until liver transplantation or death is required. ASC42 is fully self-developed by the company and is expected to be a new best-in-class highly potent and selective non-steroidal farnesoid X receptor (FXR) agonist.
5. $SenseTime-W(00020.HK)$ : SenseTime Hong Kong and JCV entered into a software license agreement
SenseTime-W Announcement, On June 8, 2022, SenseTime Hong Kong and JCV entered into a software license agreement, pursuant to which SenseTime Hong Kong agreed to license the software (computer vision products with various image recognition capabilities developed for the Group) Licenses and provides certain support services to JCV. The Software License Agreement will be effective from the date of signing.
Major issues
Ascletis Pharma-B (01672): FXR agonist ASC42 for the treatment of primary biliary cholangitis clinical trial application approved by the US FDA
Harbin Pharmaceutical-B(02142): B7H4X4-1BB Bispecific Antibody Receives New Drug Research Approval for Phase I Clinical Trials in China
Fudan Zhangjiang (01349): The clinical trial application of FDA022 antibody conjugate for injection for the treatment of advanced solid tumors has been accepted
Skyworth Group (00751) entered into a software development contract with Nanjing Coowor Zhixing
Peijia Medical-B(09996): The State Food and Drug Administration approved the registration application of Fluxcap balloon guide catheter
Zhaoke Ophthalmology-B(06622): The new drug application of cyclosporine A eye gel was accepted and reviewed by the Center for Drug Evaluation
operational data
CIFI Holdings Group (00884): Cumulative contracted sales of 49.64 billion yuan from January to May
New Town Development (01030) The contracted sales amount in May is about 11.081 billion yuan
Powerlong Properties (01238): Contracted sales in the first five months reached 19.021 billion yuan
Poly Real Estate Group (00119): The cumulative contracted sales in the first five months was 10.7 billion yuan, a year-on-year decrease of 49%
Zhongjun Group Holdings (01966): The contracted sales amount in May reached 4.790 billion yuan
M&A sale
Yimaitong (02192) plans to acquire 60% equity of Beijing Focus Innovation Technology for 48 million yuan
repurchase cancellation
AIA (01299) repurchased 1.99 million shares at a cost of HK$162 million on June 8
CMOC (03993) spent 139 million yuan to repurchase 28.6549 million A shares on June 8
Vanke (02202) spent 104 million yuan to repurchase 6 million A shares on June 8
Weichai Power (02338) spent 9.687 million yuan to repurchase 810,000 A shares on June 8
Haier Zhijia (06690) spent 28.19 million yuan to repurchase 1.15 million A shares on June 8
Changshi Group (01113) repurchased 500,000 shares at a cost of HK$26,508,200 on June 8
Sinotrans (00598) repurchased 1.896 million shares at a cost of HK$4.4073 million on June 8
HSBC Holdings (00005) repurchased approximately 3,173,300 shares on the UK and Hong Kong Stock Exchanges on June 8
Equity incentive
Sany International (00631) granted a total of 11.52 million restricted shares to 1,144 selected participants
ESR (01821) Granted 384,000 Share Options and 9,585,000 Award Shares
CIMC Enric (03899) adopted the subsidiary’s equity incentive plan to incentivize objects to subscribe for CIMC Enric’s registered capital of approximately RMB 44 million
company name change
Dingfeng Group Holdings (06878) plans to change its name to “Dingfeng Group Auto”
edit/new
This article is reprinted from: https://news.futunn.com/post/16280772?src=3&report_type=market&report_id=207703&futusource=news_headline_list
This site is for inclusion only, and the copyright belongs to the original author.